SciSparc Soars 28.68% on Patent Acquisition Sparking Sector Buzz – What’s Fueling This Surge?

Summary
• SciSparc (SPRC) surges 28.68% intraday to $3.29 after acquiring patents for MUSE™ GERD treatment system
• Turnover skyrockets 2078.93% amid strategic IP expansion and global commercialization plans
• Stock trades near 52-week low of $1.75 but hits 2025 high of $3.29 in volatile session

SciSparc’s pre-market explosion follows a binding term sheet to acquire Xylo Technologies’ endoscopic IP, including the MUSE™ system. The stock’s 28.68% rally—its largest single-day move since 2021—has drawn sector attention as the company targets the $3.03B GERD device market by 2030. With a 52-week low of $1.75 and a dynamic PE of -0.45, the move raises questions about sustainability and catalysts.

Patent Acquisition Ignites Optimism for GERD Market Expansion
SciSparc’s 28.68% surge stems from its agreement to acquire Xylo Technologies’ intellectual property, including the MUSE™ system—a single-use endoscopic device for treating GERD. The deal grants SciSparc access to a $3.03B market by 2030, with Xylo’s existing $3M licensing precedent in Greater China. The MUSE™ system’s minimally invasive design aligns with growing demand for non-surgical solutions, while SciSparc’s plan to issue 19.99% equity to Xylo signals strategic commitment. This IP acquisition, combined with recent collaborations in neuroplastogen therapies, positions the company to diversify revenue streams and capitalize on high-growth medical tech niches.

Medical Devices Sector Steady as SciSparc Surges on Patent Acquisition
While SciSparc’s stock soars, the broader Medical Devices sector remains mixed. Medtronic (MDT), the sector’s largest player, trades flat with a 0.38% intraday gain. The sector’s recent focus on AI-driven diagnostics and minimally invasive tools mirrors SciSparc’s MUSE™ strategy, but the company’s move is uniquely tied to its IP acquisition rather than macro trends. This divergence highlights SciSparc’s speculative nature compared to established peers, though its GERD market targeting aligns with sector-wide innovation in gastrointestinal solutions.

Technical Divergence and ETF Correlation Signal High-Risk, High-Reward Play
• RSI: 29.197 (oversold) • MACD: -0.356 (bullish crossover near) • 200D MA: $2.418 (price above) • Bollinger Bands: $3.44 (upper), $2.05 (lower) • 52W Range: $1.75–$37.59

SciSparc’s technicals suggest a short-term rebound after hitting 52-week lows. The RSI at 29.2 and MACD histogram turning positive indicate oversold conditions, while the stock trades above its 200D MA. However, the 52W high of $37.59 remains a distant target. Aggressive bulls may consider a breakout above $3.44 (Bollinger upper band) as a signal to scale into longs, though high volatility (8.06% weekly) demands caution. No leveraged ETFs are available for correlation analysis, but the stock’s 2078.93% turnover surge suggests strong retail participation.

Backtest SciSparc Stock Performance
Below is the back-test that evaluates “buying SciSparc (SPRC) after any session in which the share price surges ≥ 29 % intraday, then opening the position on the first day that a MACD golden-cross AND a volume spike occur.” Key take-aways are provided first, followed by an interactive results panel.1. Core findings • Total return: -99.53 % (Jan-2022 → 26-Nov-2025) • Annualised return: -12.0 % • Max-drawdown: 99.71 % → capital was almost entirely wiped out. • Risk-adjusted performance (Sharpe): -0.07, i.e. losses with volatility. • All individual trades finished negative; the strategy failed to capture sustained upside after large “pop” days.2. Interpretation • SPRC’s 29 %-plus bursts proved to be isolated liquidity spikes rather than the start of durable trends. • Follow-through momentum (MACD + volume) did not translate into price appreciation; subsequent drift was strongly negative. • The stock’s repeated reverse-splits and chronic dilution amplified downside, swamping any tactical entry edge.3. Suggested next steps • Tight stop-loss / profit-taking rules or a shorter holding window could be tested to limit deep drawdowns. • Consider adding fundamental or news filters (e.g., FDA developments) to separate genuine regime-shifts from one-day squeezes. • Apply the same trigger logic to a broader micro-cap basket to test whether the phenomenon is SPRC-specific or structural.You can inspect full statistics and trade timeline in the interactive panel below.(If the panel does not load automatically, please refresh or click the link in “backtest_result” to download the raw JSON.)

Breakout or Blip? Key Levels to Watch as SciSparc Navigates Volatility
SciSparc’s 28.68% rally hinges on its ability to execute the Xylo IP acquisition and commercialize the MUSE™ system. Immediate support at $2.75 (middle Bollinger band) and resistance at $3.44 (upper band) will dictate near-term direction. Medtronic’s 0.38% gain underscores the sector’s stability, but SciSparc’s speculative play on GERD and neurotech patents demands closer scrutiny. Investors should monitor the 200D MA ($2.418) as a critical floor and watch for follow-through volume above $3.44 to confirm a breakout. For now, the stock remains a high-risk, high-reward trade with limited options liquidity.